

# Assess cancer risk and guide personalized prevention pathways

A cost-effective and proactive solution for employers



**The Multicancer Risk Test**, part of the Quest CancerRiskIQ™, is a personalized test panel to help your employees understand their risk for certain types of cancers so they can take appropriate next steps for preventive screening.

## Cancer stats

- **New cancer diagnoses in the US exceeded 2 million** for the first time in 2024 and are projected to do so again in 2025—driven in large part by an alarming increase in cancers among younger Americans<sup>1,3</sup>
- **Approximately 50% of cancers are diagnosed at advanced stages<sup>2</sup>**
- **Oncologists report that they're now seeing more advanced-stage cancers**—stemming from significant screening delays due to the COVID-19 pandemic as well as continued screening barriers<sup>3</sup>—and worry about unfavorable outcomes and disparities in care

Yet early risk identification may lead to interventions to prevent or slow cancer development, saving your employees not just money but, crucially, their lives. As just one example, researchers found that between 1975 and 2020, screenings prevented about 80% or 4.75 million deaths due to cancer.<sup>4</sup>

# Guide personalized cancer prevention strategies with the Multicancer Risk Test

- A convenient, affordable tool that uses a single blood sample to analyze risk for multiple cancer types, including
  - Colorectal, lung, breast, pancreatic, gynecologic, liver, prostate, and upper gastrointestinal cancers
- Support with a specialized care team to
  - Help identify individuals with high risk for developing certain cancer types who would benefit from more specialized screening
- Specialized screening to help identify cancer at an earlier stage when treatments are more likely to be effective



## Prioritize proactive care



May help save lives and reduce future healthcare costs



May help improve compliance with doctor-recommended cancer screenings



Encourages employees to engage in proactive care vs reactive measures, enhancing population health



Integrates seamlessly with workplace health and safety programs



Connects to virtual provider team to guide next steps

Contact us at [WorkforceSolutions@QuestDiagnostics.com](mailto:WorkforceSolutions@QuestDiagnostics.com) to learn more about how the Multicancer Risk Test can transform cancer prevention and care for your organization

### References

1. American Cancer Society. Cancer facts and figures 2024. 2024. Accessed September 9, 2025. [cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2024/2024-cancer-facts-and-figures-ac.pdf](https://cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2024/2024-cancer-facts-and-figures-ac.pdf)
2. Crosby D, Bhatia S, Brindle KM, et al. Early detection of cancer. *Science*. 2022;375(6586):eaay9040. doi:10.1126/science.aay9040
3. Quest Diagnostics. The cancer paradox. May 2025. Accessed September 9, 2025. [newsroom.questdiagnostics.com/2025-05-13-Oncologists-Report-Seeing-More-Advanced-Cancers-and-Say-Current-Tests-Are-Not-Catching-Cancer-Recurrence-Early-Enough,-New-Quest-Diagnostics-Report-Finds](https://newsroom.questdiagnostics.com/2025-05-13-Oncologists-Report-Seeing-More-Advanced-Cancers-and-Say-Current-Tests-Are-Not-Catching-Cancer-Recurrence-Early-Enough,-New-Quest-Diagnostics-Report-Finds)
4. National Institutes of Health. Prevention and screening drive drop in cancer deaths. January 14, 2025. Accessed September 9, 2025. [nih.gov/news-events/nih-research-matters/prevention-screening-drive-drop-cancer-deaths](https://nih.gov/news-events/nih-research-matters/prevention-screening-drive-drop-cancer-deaths)

Image content features models and is intended for illustrative purposes only.

[QuestDiagnostics.com](https://www.QuestDiagnostics.com)

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. SB14367 12/2025